Searching map area
Imatinib
? TBD
Chemical compound
Join to rate
Ratings
0
Nobody has rated this yet. Be the first!
Subject of
18
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia
article by Simona Soverini et al published 15 December 2006 in Clinical Cancer Research
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party
article by Gabriele Gugliotta et al published 26 May 2011 in Blood
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis
scientific article
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate
scientific article published on 10 August 2007
Imatinib: A Viewpoint by Brian J. Druker
scientific article published on 01 January 2001
Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia
article
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
article
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o
article by Simona Soverini et al published 20 June 2005 in Journal of Clinical Oncology
Potential role of imatinib mesylate (Gleevec, STI-571) in the treatment of vestibular schwannoma
scientific article published on January 2011
Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis
scientific article
8 more
Lists
0
Join to rate

Imatinib, sold under the brand names Gleevec and Glivec (both marketed worldwide by Novartis) among others, is an oral targeted therapy medication used to treat cancer. Imatinib is a small molecule inhibitor targeting multiple tyrosine kinases such as CSF1R, ABL, c-KIT, FLT3, and PDGFR-β. Specifically, it is used for chronic myelogenous leukemia...

Instance of
type of chemical entity
Subclass of
Chemical compound
Wikidata